Hypertension and COVID-19: Updates from the era of vaccines and variants

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Sowmya Swamy , Christian A. Koch , Fady Hannah-Shmouni , Ernesto L. Schiffrin , Joanna Klubo-Gwiezdzinska , Sriram Gubbi
{"title":"Hypertension and COVID-19: Updates from the era of vaccines and variants","authors":"Sowmya Swamy ,&nbsp;Christian A. Koch ,&nbsp;Fady Hannah-Shmouni ,&nbsp;Ernesto L. Schiffrin ,&nbsp;Joanna Klubo-Gwiezdzinska ,&nbsp;Sriram Gubbi","doi":"10.1016/j.jcte.2021.100285","DOIUrl":null,"url":null,"abstract":"<div><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associated with increased risk for severe disease and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied since the onset of the pandemic. This review discusses the potential pathophysiologic interactions between hypertension and COVID-19 and provides an up-to-date information on the implications of newly emerging SARS-CoV-2 variants, and vaccines on patients with hypertension.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/87/main.PMC8645507.pdf","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214623721000375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 14

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associated with increased risk for severe disease and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied since the onset of the pandemic. This review discusses the potential pathophysiologic interactions between hypertension and COVID-19 and provides an up-to-date information on the implications of newly emerging SARS-CoV-2 variants, and vaccines on patients with hypertension.

Abstract Image

高血压和COVID-19:来自疫苗和变体时代的最新情况。
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是2019年冠状病毒病(新冠肺炎)的病原体,是全球发病率和死亡率的主要原因。新冠肺炎患者年龄较大以及代谢综合征某些成分(包括高血压)的存在与重症和死亡风险增加有关。自新冠肺炎大流行以来,抗高血压药物在其发病机制中的作用已被广泛研究。这篇综述讨论了高血压与新冠肺炎之间潜在的病理生理相互作用,并提供了关于新出现的SARS-CoV-2变异和疫苗对高血压患者的影响的最新信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
24
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信